|
KR101483215B1
(ko)
*
|
2010-01-29 |
2015-01-16 |
한미약품 주식회사 |
단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
|
|
JP5985473B2
(ja)
*
|
2010-07-13 |
2016-09-06 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ＩＲＡＫ４モジュレーターとしてのピラゾロ［１，５ａ］ピリミジン及びチエノ［３，２ｂ］ピリミジン誘導体
|
|
EP3239154A1
(en)
*
|
2011-01-10 |
2017-11-01 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
EP2688872A4
(en)
*
|
2011-03-22 |
2014-08-27 |
Merck Sharp & Dohme |
AMIDOPYRAZOLHEMMER OF INTERLEUKIN RECEPTOR-MEDIATED KINASES
|
|
WO2012178125A1
(en)
|
2011-06-22 |
2012-12-27 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
SG11201402765TA
(en)
*
|
2011-12-30 |
2014-06-27 |
Hanmi Pharm Ind Co Ltd |
THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES
|
|
TW201728592A
(zh)
*
|
2012-01-10 |
2017-08-16 |
林伯士艾瑞斯公司 |
Ｉｒａｋ抑制劑及其用途
|
|
JP6109193B2
(ja)
*
|
2012-01-10 |
2017-04-05 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
チエノピリミジン化合物
|
|
WO2014003483A1
(en)
*
|
2012-06-29 |
2014-01-03 |
Hanmi Pharm. Co., Ltd. |
Fused pyrimidine derivatives having inhibitory activity on fms kinases
|
|
BR112015000399A2
(pt)
*
|
2012-07-10 |
2017-06-27 |
Ares Trading Sa |
derivados de pirazolil pirimidina
|
|
HK1210732A1
(en)
|
2012-07-11 |
2016-05-06 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
EP2872144A4
(en)
|
2012-07-11 |
2015-12-02 |
Nimbus Iris Inc |
IRAQ INHIBITOR AND USES THEREOF
|
|
WO2014011911A2
(en)
*
|
2012-07-11 |
2014-01-16 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
LT3418281T
(lt)
|
2012-12-07 |
2021-01-11 |
Vertex Pharmaceuticals Inc. |
Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
|
|
WO2014110114A1
(en)
|
2013-01-10 |
2014-07-17 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
EP2943485B1
(en)
|
2013-01-14 |
2017-09-20 |
Incyte Holdings Corporation |
Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
|
|
TWI662030B
(zh)
|
2013-01-15 |
2019-06-11 |
英塞特控股公司 |
適用作ｐｉｍ激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物
|
|
US8778365B1
(en)
|
2013-01-31 |
2014-07-15 |
Merz Pharmaceuticals, Llc |
Topical compositions and methods for making and using same
|
|
WO2014143240A1
(en)
|
2013-03-15 |
2014-09-18 |
Vertex Pharmaceuticals Incorporated |
Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
|
|
EP2970288A1
(en)
*
|
2013-03-15 |
2016-01-20 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
EP2970289A1
(en)
|
2013-03-15 |
2016-01-20 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
US20160166576A1
(en)
|
2013-07-11 |
2016-06-16 |
Merck Sharp & Dohme Corp. |
Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
|
|
US9556197B2
(en)
*
|
2013-08-23 |
2017-01-31 |
Incyte Corporation |
Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
|
|
EP3049086A4
(en)
|
2013-09-27 |
2017-02-22 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
HUE046727T2
(hu)
|
2013-12-06 |
2020-03-30 |
Vertex Pharma |
Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
|
|
USRE50030E1
(en)
|
2013-12-13 |
2024-07-02 |
Dana-Farber Cancer Institute, Inc. |
Methods to treat lymphoplasmacytic lymphoma
|
|
EP3079682A4
(en)
|
2013-12-13 |
2017-08-30 |
Dana-Farber Cancer Institute, Inc. |
Methods to treat lymphoplasmacytic lymphoma
|
|
TWI667233B
(zh)
|
2013-12-19 |
2019-08-01 |
德商拜耳製藥公司 |
新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
|
|
HK1231480A1
(zh)
*
|
2014-01-10 |
2017-12-22 |
Aurigene Discovery Technologies Limited |
作为irak4抑制剂的吲唑化合物
|
|
IL311677B2
(en)
|
2014-01-13 |
2025-06-01 |
Aurigene Oncology Ltd |
Bicyclic heterocyclyl derivatives as irak4 inhibitors
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
HRP20210935T1
(hr)
*
|
2014-05-23 |
2021-08-06 |
F. Hoffmann - La Roche Ag |
Spojevi 5-kloro-2-difluorometoksifenil pirazolopirimidina koji predstavljaju inhibitore jak
|
|
ES2777608T3
(es)
|
2014-06-05 |
2020-08-05 |
Vertex Pharma |
Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo
|
|
US11179394B2
(en)
|
2014-06-17 |
2021-11-23 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of Chk1 and ATR inhibitors
|
|
WO2016010897A1
(en)
|
2014-07-14 |
2016-01-21 |
Incyte Corporation |
Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
|
|
US9580418B2
(en)
|
2014-07-14 |
2017-02-28 |
Incyte Corporation |
Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
|
|
CA2965178C
(en)
|
2014-10-22 |
2023-09-26 |
Dana-Farber Cancer Institute, Inc. |
Thiazolyl-containing compounds for treating proliferative diseases
|
|
WO2016073889A1
(en)
|
2014-11-06 |
2016-05-12 |
Lysosomal Therapeutics Inc. |
Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
|
|
EP3215511B1
(en)
*
|
2014-11-06 |
2024-04-17 |
Bial-R&D Investments, S.A. |
Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
|
|
US20180185368A1
(en)
|
2014-11-06 |
2018-07-05 |
Lysosomal Therapeutics Inc. |
Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
|
|
LT3221306T
(lt)
*
|
2014-11-20 |
2020-03-10 |
Merck Patent Gmbh |
Heteroarilo junginiai, kaip irak inhibitoriai ir jų panaudojimas
|
|
US10329294B2
(en)
|
2015-03-12 |
2019-06-25 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidine inhibitors of IRAK4 activity
|
|
US10155765B2
(en)
|
2015-03-12 |
2018-12-18 |
Merck Sharp & Dohme Corp. |
Carboxamide inhibitors of IRAK4 activity
|
|
US10329295B2
(en)
|
2015-03-12 |
2019-06-25 |
Merck Sharp & Dohme Corp. |
Pyrrolotriazine inhibitors of IRAK4 activity
|
|
US10040798B2
(en)
|
2015-03-12 |
2018-08-07 |
Merck Sharp & Dohme Corp. |
Pyrrolopyridazine inhibitors of IRAK4 activity
|
|
US10040802B2
(en)
|
2015-03-12 |
2018-08-07 |
Merck Sharp & Dohme Corp. |
Thienopyrazine inhibitors of IRAK4 activity
|
|
WO2016196244A1
(en)
|
2015-05-29 |
2016-12-08 |
Incyte Corporation |
Pyridineamine compounds useful as pim kinase inhibitors
|
|
WO2017004134A1
(en)
*
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
CA2992406A1
(en)
*
|
2015-07-15 |
2017-01-19 |
Aurigene Discovery Technologies Limited |
Indazole and azaindazole compounds as irak-4 inhibitors
|
|
AR105967A1
(es)
|
2015-09-09 |
2017-11-29 |
Incyte Corp |
Sales de un inhibidor de pim quinasa
|
|
KR102768838B1
(ko)
|
2015-09-17 |
2025-02-14 |
시티 오브 호프 |
Pcna 억제제
|
|
CN105237414B
(zh)
*
|
2015-09-30 |
2017-03-22 |
浙江永宁药业股份有限公司 |
ivacaftor中间体及其制备方法和用途
|
|
US11464774B2
(en)
|
2015-09-30 |
2022-10-11 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
|
|
WO2017059251A1
(en)
|
2015-10-02 |
2017-04-06 |
Incyte Corporation |
Heterocyclic compounds useful as pim kinase inhibitors
|
|
EP3394066A2
(en)
|
2015-12-22 |
2018-10-31 |
H. Hoffnabb-La Roche Ag |
PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
|
|
KR20180133461A
(ko)
|
2016-04-06 |
2018-12-14 |
리소소말 테라퓨틱스 인크. |
피라졸로[1,5-a]피리미디닐 카르복스아미드 화합물 및 의학적 장애의 치료에서의 그의 용도
|
|
WO2017176961A1
(en)
|
2016-04-06 |
2017-10-12 |
Lysosomal Therapeutics Inc. |
Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
|
|
MX388912B
(es)
|
2016-04-06 |
2025-03-20 |
Lysosomal Therapeutics Inc |
Compuestos de pirrol[1,2-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos
|
|
EP3452045A1
(en)
*
|
2016-05-04 |
2019-03-13 |
Lysosomal Therapeutics Inc. |
Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds
|
|
WO2017192931A1
(en)
|
2016-05-05 |
2017-11-09 |
Lysosomal Therapeutics Inc. |
SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
|
|
WO2017192930A1
(en)
|
2016-05-05 |
2017-11-09 |
Lysosomal Therapeutics Inc. |
SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
|
|
CN106222183B
(zh)
*
|
2016-07-25 |
2019-11-08 |
南通大学 |
靶向人irak1基因的小干扰rna及其应用
|
|
WO2018083085A1
(en)
|
2016-11-02 |
2018-05-11 |
F. Hoffmann-La Roche Ag |
PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
|
|
WO2018142393A1
(en)
|
2017-02-01 |
2018-08-09 |
Yissum Research Development Company Of The Hebrew |
N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors for treating cancer
|
|
TW202340194A
(zh)
|
2017-02-16 |
2023-10-16 |
美商基利科學股份有限公司 |
吡咯并[1,2-b]嗒𠯤衍生物
|
|
CN120267671A
(zh)
|
2017-03-31 |
2025-07-08 |
奥锐金肿瘤有限公司 |
用于治疗血液病的化合物和组合物
|
|
CN106946890A
(zh)
*
|
2017-04-26 |
2017-07-14 |
中国药科大学 |
吡啶类irak4抑制剂、其制备方法及应用
|
|
JP7256757B2
(ja)
|
2017-05-22 |
2023-04-12 |
エフ． ホフマン－ラ ロシュ アーゲー |
処置用化合物及び組成物、並びにその使用方法
|
|
CN110785418A
(zh)
*
|
2017-06-21 |
2020-02-11 |
豪夫迈·罗氏有限公司 |
作为irak4调节剂的异二氢吲哚酮衍生物
|
|
JP2020524692A
(ja)
*
|
2017-06-21 |
2020-08-20 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｉｒａｋ４調節因子としてのベンゾフラン
|
|
WO2018234345A1
(en)
*
|
2017-06-21 |
2018-12-27 |
F. Hoffmann-La Roche Ag |
PYRAZOLO [1,5A] PYRIMIDINE DERIVATIVES AS MODULATORS OF IRAK4
|
|
WO2019001460A1
(zh)
*
|
2017-06-27 |
2019-01-03 |
南京明德新药研发股份有限公司 |
作为 irak4 抑制剂的稠环化合物
|
|
JP7114394B2
(ja)
*
|
2017-08-18 |
2022-08-08 |
住友化学株式会社 |
化合物、レジスト組成物及びレジストパターンの製造方法
|
|
MX2020003190A
(es)
|
2017-09-22 |
2020-11-11 |
Kymera Therapeutics Inc |
Degradadores de proteinas y usos de los mismos.
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
EP4410377A3
(en)
|
2017-10-31 |
2024-11-13 |
Curis, Inc. |
Compounds and compositions for treating hematological disorders
|
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
|
BR112020010905A2
(pt)
*
|
2017-11-30 |
2020-11-17 |
Hanmi Pharm. Co., Ltd. |
compostos, composição farmacêutica e uso de um composto ou da composiçao farmacêutica
|
|
TW201924683A
(zh)
|
2017-12-08 |
2019-07-01 |
美商英塞特公司 |
用於治療骨髓增生性贅瘤的低劑量組合療法
|
|
WO2019111218A1
(en)
|
2017-12-08 |
2019-06-13 |
Cadila Healthcare Limited |
Novel heterocyclic compounds as irak4 inhibitors
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
|
|
EP3774797B1
(en)
*
|
2018-04-05 |
2025-11-19 |
Merck Patent GmbH |
Heteroaryl compounds as type ii irak inhibitors and uses hereof
|
|
US12454520B2
(en)
|
2018-07-06 |
2025-10-28 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
TWI721483B
(zh)
|
2018-07-13 |
2021-03-11 |
美商基利科學股份有限公司 |
吡咯并[1,2-b]嗒𠯤衍生物
|
|
CN110862375B
(zh)
|
2018-08-27 |
2022-10-25 |
深圳铂立健医药有限公司 |
吡唑化合物及其药物组合物和应用
|
|
KR20250174699A
(ko)
|
2018-10-30 |
2025-12-12 |
크로노스 바이오, 인코포레이티드 |
Cdk9 활성을 조절하기 위한 화합물, 조성물 및 방법
|
|
AU2019389174A1
(en)
|
2018-11-30 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
KR20220027196A
(ko)
*
|
2019-06-27 |
2022-03-07 |
바이오젠 엠에이 인코포레이티드 |
이미다조[1,2-a]피리디닐 유도체 및 질병의 치료에서 이것들의 용도
|
|
PH12022500002A1
(en)
|
2019-06-28 |
2023-04-03 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
US12558427B2
(en)
|
2019-07-17 |
2026-02-24 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
KR102782229B1
(ko)
|
2019-10-02 |
2025-03-20 |
(주)카이노스메드 |
N-(1h-이미다졸-2-일)벤즈아미드 화합물 및 활성 성분으로 이를 포함하는 약학 조성물
|
|
WO2021119159A1
(en)
|
2019-12-10 |
2021-06-17 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
CA3161878A1
(en)
|
2019-12-17 |
2021-06-24 |
Matthew M. Weiss |
Irak degraders and uses thereof
|
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
|
BR112022020020A2
(pt)
|
2020-04-04 |
2022-11-22 |
Pfizer |
Métodos de tratamento da doença do coronavírus 2019
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
EP4161521A4
(en)
|
2020-06-03 |
2024-07-10 |
Kymera Therapeutics, Inc. |
DEUTERED IRAQ DEGRADERS AND USES THEREOF
|
|
CA3194164A1
(en)
*
|
2020-09-30 |
2022-04-07 |
Koichiro Arai |
Pyrimidine- and nitrogen-containing bicyclic compound
|
|
EP4247790B1
(en)
|
2020-11-23 |
2024-10-09 |
Regor Pharmaceuticals, Inc. |
Sting antagonists and uses thereof
|
|
US11866405B2
(en)
|
2020-12-10 |
2024-01-09 |
Astrazeneca Ab |
Substituted indazoles as IRAK4 inhibitors
|
|
AR124547A1
(es)
|
2020-12-30 |
2023-04-05 |
Kymera Therapeutics Inc |
Degradadores de irak y sus usos
|
|
WO2022174268A1
(en)
|
2021-02-15 |
2022-08-18 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
MX2023009178A
(es)
|
2021-02-15 |
2023-08-21 |
Kymera Therapeutics Inc |
Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
|
|
CA3214747A1
(en)
|
2021-04-08 |
2022-10-13 |
Reinhard Von Roemeling |
Combination therapies for the treatment of cancer
|
|
CA3217792A1
(en)
|
2021-05-07 |
2022-11-10 |
Kymera Therapeutics, Inc |
Cdk2 degraders and uses thereof
|
|
KR102869914B1
(ko)
*
|
2021-10-28 |
2025-10-13 |
재단법인 대구경북첨단의료산업진흥재단 |
신규한 티에노[2,3-d]피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 자가면역질환의 예방 또는 치료용 약학적 조성물
|
|
JP2024540080A
(ja)
|
2021-10-29 |
2024-10-31 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ４分解剤およびその合成
|
|
EP4472967A4
(en)
|
2022-01-31 |
2026-04-15 |
Kymera Therapeutics Inc |
Iraqi Degradation Agents and Their Uses
|